Letter to the editor
Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome
Article first published online: 10 JAN 2013
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society
British Journal of Clinical Pharmacology
Volume 75, Issue 2, pages 565–568, February 2013
How to Cite
Coutsouvelis, J., Wiseman, M., Hui, L., Poole, S., Dooley, M., Patil, S., Avery, S., Wei, A. and Spencer, A. (2013), Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome. British Journal of Clinical Pharmacology, 75: 565–568. doi: 10.1111/j.1365-2125.2012.04355.x
- Issue published online: 10 JAN 2013
- Article first published online: 10 JAN 2013
- Accepted manuscript online: 11 JUN 2012 08:50AM EST
- Manuscript Accepted: 1 JUN 2012
- Manuscript Received: 6 MAR 2012
- 1Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149: 578–586., , , .
- 6A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol 2010; 85: 177–179., .
- 9Sanofi-Aventis. Fasturtec (Rasburicase) Approved Product Information. Macquarie Park: Sanofi-Aventis Australia Pty Ltd, 2010.
- 13Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia – successful treatment and prevention of TLS with low-dose rasburicase. Eur J Haematol 2005; 75: 518–521., , , , , .